ABCG2 is a transporter protein of the ATP-binding-cassette (ABC) family that is expressed in the plasma membrane in cells of various tissues and tissue barriers, including the blood-brain, blood-testis and maternal-fetal barriers 1-4 . Powered by ATP, it translocates endogenous substrates, affects the pharmacokinetics of many drugs and protects against a wide array of xenobiotics, including anti-cancer drugs 5-12 . Previous studies have revealed the architecture of ABCG2 and the structural basis of its inhibition by small molecules and antibodies 13,14 . However, the mechanisms of substrate recognition and ATP-driven transport are unknown. Here we present high-resolution cryo-electron microscopy (cryo-EM) structures of human ABCG2 in a substrate-bound pre-translocation state and an ATP-bound post-translocation state. For both structures, we used a mutant containing a glutamine replacing the catalytic glutamate (ABCG2 EQ ), which resulted in reduced ATPase and transport rates and facilitated conformational trapping for structural studies. In the substrate-bound state, a single molecule of estrone-3-sulfate (E 1 S) is bound in a central, hydrophobic and cytoplasm-facing cavity about halfway across the membrane. Only one molecule of E 1 S can bind in the observed binding mode. In the ATP-bound state, the substrate-binding cavity has collapsed while an external cavity has opened to the extracellular side of the membrane. The ATP-induced conformational changes include rigid-body shifts of the transmembrane domains, pivoting of the nucleotide-binding domains (NBDs), and a change in the relative orientation of the NBD subdomains. Mutagenesis and in vitro characterization of transport and ATPase activities demonstrate the roles of specific residues in substrate recognition, including a leucine residue that forms a 'plug' between the two cavities. Our results show how ABCG2 harnesses the energy of ATP binding to extrude E 1 S and other substrates, and suggest that the size and binding affinity of compounds are important for distinguishing substrates from inhibitors.
could fit only one E 1 S molecule but given that ABCG2 has two-fold symmetry, E 1 S can be bound in two orientations related by a 180° rotation ( Fig. 2a, b and Extended Data Fig. 4b ). Two E 1 S molecules cannot bind simultaneously because their polycyclic ring systems would clash sterically. The strongest density was at the two-fold symmetry axis, where the core of the flat polycyclic ring binds, and reprocessing the data with C1 symmetry resulted in a very similar-albeit lowerresolution-electron microscopy map (Extended Data Fig. 4b, c ). The substrate-binding cavity was shown previously to accommodate potent inhibitors, demonstrating its dual role in substrate and multidrug binding 14 (Fig. 2c) .
The ABCG2 EQ -E 1 S structure revealed which residues interacted with bound substrate (Fig. 2d ). We generated single point mutations of all of these residues, and determined the in vitro ATPase and E 1 S transport activities of the resulting ABCG2 variants upon reconstitution of the purified proteins in proteoliposomes ( Fig. 2e, f) . The stability of all mutants tested was similar to that of the wild-type protein (Extended Data Fig. 5a ), allowing direct comparison. We also determined the EC 50 values of E 1 S-induced ATPase stimulation for all mutants (Extended Data Fig. 5b, c) . Consistent with their role in binding E 1 S, the transport activities of the mutants N436A and F439A were strongly reduced, as were their ATPase activities. Notably, neither the N436A nor the F439A mutant showed stimulation of their ATPase activity by E 1 S, indicating that the interactions suggested by the structure (a hydrogen bond between N436 and the sulfate group of E 1 S, and the stacking interaction of the phenyl ring of F439 to the ring system of E 1 S) are important for substrate binding (Fig. 2 and Extended Data Fig. 5b , c). The V546F mutant had impaired transport activity but displayed a 12-fold increase in basal ATPase activity, which was inhibited by E 1 S in a concentrationdependent manner. This could suggest that the introduction of two phenyl rings at this position of the substrate-binding cavity mimics the binding of a substrate and thus stimulates ATPase activity, whereas further addition of E 1 S 'clogs' the transporter.
The V546A mutant, by contrast, had similar functional characteristics to the wild-type protein, with a slight increase in the EC 50 of E 1 S stimulation. It has previously been reported that in the ABCG5/ABCG8 heterodimeric protein, the mutations Y432A and A540F (equivalent to F439A and V546F in ABCG2) disrupted cholesterol transport 17 , suggesting a common location for the substrate-binding site among G-subfamily ABC transporters. We further found that the mutation T435A caused a roughly 4.5-fold increase in the apparent EC 50 of ATPase stimulation, consistent with our interpretation from the structure that a hydrogen bond exists between the β-hydroxyl group of T435 and the ester group of E 1 S. There was a twofold increase in transport in the T435A mutant, suggesting an inverse relationship between binding affinity and the maximal transport rate. The introduction of two phenylalanines (T435F mutant) impaired both E 1 S transport and ATP hydrolysis-a different effect to that seen with V546F. This emphasizes the sensitivity of the binding cavity to modifications. Finally, the M549A mutant had similar ATPase and transport activities Letter reSeArCH to the wild-type protein, suggesting a minor contribution of this residue to E 1 S binding.
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To visualize ATP-driven conformational changes in ABCG2, we added ATP and magnesium to nanodisc-reconstituted ABCG2 EQ in the absence of 5D3-Fab (ABCG2 EQ -ATP). Cryo-EM analysis revealed that most particles featured an ATP-bound conformation with the NBD dimer closed, and no inward-facing classes ( Fig. 1 and Extended Data Fig. 6 ). The overall resolution was 3.1 Å, with excellent side-chain density for the TMDs, NBDs and nucleotides (Extended Data Fig. 4d and Extended Data Table 1 ). The structure revealed a closed, 'head-to-tail' NBD dimer, featuring a much larger interface than in the nucleotidefree state, and forming two ATP-binding sites between the Walker A motif (another phosphate-binding loop, or P-loop) of one NBD and the signature sequence (VSGGE sequence) of the other (Fig. 1b ). ATP molecules are bound, and there is clear electron microscopy density for a magnesium ion interacting with the βand γ-phosphates of each ATP (Fig. 1b ). Three conserved side chains coordinate the γ-phosphate of ATP: Q211 (corresponding to the catalytic glutamate in wild-type ABCG2); H243 (corresponding to the 'switch' histidine 18 ); and Q126 (which is part of the Q-loop). Q211 also coordinates the magnesium ion. ABCG2 does not contain an A-loop with an aromatic side chain stacking against the adenine moiety, as is seen in many other ABC transporters [19] [20] [21] [22] . Rather, one face of the adenine ring is in Van der Waals distance of residues V46, I63 and G185 from one NBD; the other face stacks against R184 from the opposite NBD. R184 also forms a salt bridge with the α-phosphate, which was observed previously in the AMPPNP-bound structure of the bacterial B12 transporter BtuCDF 23 . The NBD interface of ATP-bound ABCG2 EQ also contains a salt bridge formed by E127 (part of the Q-loop) and R191 adjacent to the signature motif. Unlike in B-family ABC transporters, there is a hole at the interface of the four domains of ABCG2, rather similar to what was seen in BtuCDF ( Fig. 1a ).
As a result of ATP binding, the α-helical domains of the NBDs have rotated by roughly 35° relative to the RecA-like domains, approaching the opposite NBD and the two-fold symmetry axis ( Fig. 3a ). This rotation is required for NBD dimerization and is part of the 'power stroke' in the transport cycle 24 . The individual TMD-NBD interfaces-formed mainly by the 'connecting helices' (CnH or TM1a) and 'coupling helices' (CpH, corresponding to the carboxy-terminal part of TM2)-remain largely unchanged in each ABCG2 monomer between the nucleotidefree and ATP-bound states (Fig. 3b ). However, because of the shift in the NBDs, the cytoplasmic parts of the TMDs are pushed towards each other, with each CpH approaching the two-fold symmetry axis by around 7 Å (Fig. 3c ). The altered conformations of the TMDs can be described as rigid-body movements, with CnH and CpH acting as the pivot points for the transition. These two α-helices undergo a roughly 20° rotation when superposing the NBDs in the structures of the two states, which translates to a roughly 40° rotation of the helical axes of the TMDs (Fig. 3d ).
The ATP-induced conformational changes have important consequences for the substrate-translocation pathway. In the ABCG2 EQ -E 1 S structure, the phenyl rings of the F439 residues of the two ABCG2 monomers are 8.0 Å apart, with bound E 1 S between them ( Fig. 2d ). By contrast, these phenyl rings stack against each other in the ATPbound state (Fig. 4a , c) and the substrate-binding cavity has completely collapsed, with no space for bound substrate. To be transported across the membrane, therefore, the substrate has to move through the likely translocation pathway at the centre of the transporter and reach the external cavity before the pathway is completely closed. This can be accomplished only if there are transient conformational changes such as TM-helix bending, to generate space for the substrate. Such transient changes resemble a peristaltic motion.
The external cavity-occluded in the nucleotide-free state-is open to the outside in the ATP-bound state, while maintaining the intra-and intermolecular disulfides (C592-C608 and C603-C603′) in extracellular loop 3 (EL3), promoting substrate release (Figs. 1a, 4d and Extended Data Figs. 1b, 6e). Two leucine residues (L554 and L555), in the loop between TM5a and TM5b, form a plug that separates the substrate-binding cavity and the external cavity ( Fig. 4 ). We individually mutated these leucines to alanines and found that the L555A variant did not express any functional protein, suggesting a structural role of L555 in addition to a likely gating function. By contrast, the L554A mutant was stable and showed functional differences compared to wild-type ABCG2 ( Fig. 2e , f and Extended Data Fig. 5 ): the basal ATPase rate of L554A was greatly increased and there was only a minor stimulation of the ATPase rate by E 1 S (around 20%, compared with roughly 3.5-fold in wild-type ABCG2). Furthermore, the apparent EC 50 of E 1 S-induced ATPase stimulation was increased, suggesting weaker substrate binding. Finally, the E 1 S transport activity of the L554A mutant was twice as high as that of wild-type ABCG2. We interpret that the opening and closing of the 'leucine plug' may act as a checkpoint during the transport reaction, and that although the removal of the leucine side chain accelerates the transport process, it may reduce substrate selectivity.
A comparison of the structures shown here provides insight into the transport cycle of ABCG2. Substrate may bind via the cytoplasm or from within the lipid bilayer via the 'membrane entrance' 14 ( Fig. 4b ).
Once substrate is bound, the NBD dimer can only close when the substrate moves out of the substrate-binding cavity, because this cavity does not provide any space when ATP is also bound. In a productive transport cycle, substrate probably moves through a translocation pathway at the centre of the transporter, via the 'leucine plug' . The structure of ATP-bound ABCG2 EQ suggests that once a substrate clears the plug area and enters the external cavity, the plug region closes and substrate is released to the outside (Fig. 4d ). One caveat is that the E211Q mutation may have influenced the energetics of the conformational changes 
involved. Our findings suggest that ATP binding might be sufficient for the substrate-extrusion step and that ATP hydrolysis might be required to reset the transporter to an inward-facing conformation 19, 20, 25, 26 . Unlike many other transporters 22, [27] [28] [29] [30] , ABCG2 does not appear to form a stable, occluded conformation providing space for bound substrate, but rather a transient conformation that is consistent with a peristalsislike mechanism, reminiscent of the bacterial BtuCDF transporter.
Given their polyspecificity, a key unanswered question concerning multidrug transporters such as ABCG2 is why certain compounds act as substrates, while others are potent inhibitors. Our results allow us to compare the binding modes of a bona fide ABCG2 substrate with those of two potent inhibitors. All three molecules bind in the same cavity of the transporter (Fig. 2c ). However, whereas a single E 1 S molecule binds on the two-fold symmetry axis and deep in the cavity, two molecules of MZ29-a compound derived from the ABCG2 inhibitor Ko143-have been found to fill the substrate-binding cavity completely, almost reaching the cytoplasmic membrane boundary and forming many additional contacts with the surface of ABCG2 (ref. 14 ) . A single copy of the tariquidarderived inhibitor MB136 also fills the binding cavity completely, forming similar contacts to MZ29. The numerous additional contacts, which include residues of TM1b in addition to TM2 and TM5a, can explain the increased binding affinity of inhibitors compared with substrates. The difference appears to mean that when E 1 S and ATP are bound to ABCG2, the NBDs and the cytoplasmic part of the TMDs can still approach, allowing for an opening of the plug and simultaneous pushing of the substrate into the external cavity. Inhibitors, by contrast, act as 'wedges' and immobilize the transporter by locking it in an inward-facing conformation. The reduced size, binding surface and affinity of substrates, and their binding deeper inside the substrate cavity, allow them to be translocated in a productive transport cycle.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0680-3. Residues lining the substrate-binding cavity are shown as sticks; bound E 1 S has been omitted for clarity. The dashed line shows the distance between the two F439 residues that stack against bound E 1 S. b, Vertical slice through a surface representation of ABCG2 EQ -E 1 S, with bound E 1 S shown as pink spheres and the two cavities and plug region labelled. In the right-hand panel, a 90° rotation of the structure reveals the fit of E 1 S in the substrate-binding cavity, as viewed from the cytoplasm. The NBDs have been removed for clarity. c, d, As for a, b, but with the ABCG2 EQ -ATP structure. In the right-hand panel of d, the molecular surface of the external cavity, viewed from the extracellular space and colour-coded by electrostatic potential ranging from blue (most positive) to red (most negative), is shown with the extracellular loop EL3 removed for clarity. Letter reSeArCH
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Expression and purification of wild-type and mutant human ABCG2. Human ABCG2, containing an amino (N)-terminal Flag tag, was expressed in HEK293-EBNA (Thermo Fisher Scientific) cells and purified as described 13, 14 . Expression and purification of 5D3-Fab. 5D3 hybridoma cells, producing the 5D3 monoclonal antibody, were obtained from B. Sorrentino. The cells were cultured in WHEATON CELLine Bioreactors, according to the manufacturer's protocol, and 5D3-Fab was then purified from the supernatant, as described in the Fab Preparation Kit protocol (Thermo Fisher Scientific). Nanodisc preparation of ABCG2 EQ . The membrane scaffold protein (MSP) 1D1 was expressed and purified 31 and ABCG2 was reconstituted into brain polar lipid (BPL)/cholesterol hemisuccinate (CHS) nanodiscs as described 13, 14 . To generate the ABCG2 EQ -E 1 S sample for cryo-EM studies, ABCG2 was first mixed with a threefold molar excess of 5D3-Fab before reconstitution. After size-exclusion chromatography (SEC) using a Superdex 200 10/300 column (GE Healthcare), the complex was incubated with 200 µM E 1 S, 5 mM ATP and 5 mM MgCl 2 for 15 min at room temperature before grid preparation. For the ABCG2 EQ -ATP sample, following SEC, the complex was incubated with 5 mM ATP and 5 mM MgCl 2 for 15 min at room temperature before grid preparation. ABCG2 liposome preparation. A BPL/cholesterol (Avanti Polar Lipids) mixture was prepared at a 4/1 (w/w) ratio as described 32 . Detergent-purified ABCG2 was then mixed with BPL/cholesterol; detergent was removed with Bio-Beads and the reconstitution efficiency determined 13, 14, 33 . Transport assays. In vitro transport assays using ABCG2 proteoliposomes, containing either wild-type or mutant protein, were carried out as described. In brief, ABCG2 proteoliposomes were extruded and then incubated with 5 mM MgCl 2 and 50 µM [ 3 H]-E 1 S for 5 min at 30 °C. The transport reaction was initiated by the addition of 2 mM ATP and the sample was filtered using a Multiscreen vacuum manifold (MSFBN6B filter plate, Millipore). Radioactivity trapped on the filters was measured using a scintillation counter and the initial transport rates (over 30 seconds to 2 minutes) were determined using linear regression in GraphPad Prism 7.00. Rates were corrected for the orientation of ABCG2 in proteoliposomes 13, 14 . ATPase assays and determination of the EC 50 of E 1 S stimulation. ATP-hydrolysis activity was measured using a previously described technique 34 . All reactions were performed at 37 °C in the presence of 2 mM ATP and 10 mM MgCl 2 13, 14 . For ATPase assays in proteoliposomes, experiments were completed in the presence of 0-300 µM E 1 S. To assess the effect of 5D3-Fab, ABCG2 proteoliposomes were freeze-thawed five times in the presence of a threefold molar excess of 5D3-Fab (to ensure that the antibody was present inside the proteoliposomes) before extrusion. Assays in nanodiscs were performed in the absence of E 1 S. Data were recorded at four time intervals (0, 5, 15 and 30 min) and subsequent ATPase rates were determined using linear regression in GraphPad Prism 7.00. Rates were corrected for the orientation of ABCG2 in proteoliposomes. To determine the EC 50 of E 1 S stimulation, we plotted the ATPase rates against the E 1 S concentration, and generated curves using the nonlinear regression Michaelis-Menten analysis tool in GraphPad Prism 7.00. Sample preparation and cryo-EM data acquisition. All cryo grids of ABCG2 EQ were prepared using a Vitrobot Mark IV (FEI) with the environmental chamber set at 100% humidity and 4 °C. An aliquot of 4 µl purified ABCG2 EQ -E 1 S or ABCG2 EQ -ATP, at a protein concentration of approximately 0.4 mg ml −1 , was applied to glow-discharged Quantifoil (1.2/1.3) 300-mesh copper grids. After being blotted with filter paper for 2.0 s, the grids were flash-frozen in a mixture of propane and ethane cooled with liquid nitrogen. The ABCG2 EQ -E 1 S dataset was composed of 3,984 movies and the ABCG2 EQ -ATP dataset was composed of 4,905 movies. Cryo-EM image data were recorded using SerialEM 35 on a Titan Krios microscope, operated at 300 kV and equipped with a Gatan Quantum-LS energy filter (20 eV zero loss filtering), containing a K2 Summit direct electron detector. Images were recorded in super-resolution counting mode with a pixel size of 0.4058 Å per pixel. Exposures were 10 s, dose-fractionated into 50 frames (0.2 s per frame), resulting in a frame dose of 2.0 electrons per Å 2 . Data-collection quality was monitored using Focus 36 . The first frame of each movie was discarded. Stacks were gain-normalized, motion-corrected, dose-weighted and averaged and then Fourier-cropped twofold with MotionCor2 (ref. 37 ). Defocus estimates were obtained on the non-dose-weighted micrographs with CTFFIND4 (ref. 38 ) for ABCG2 EQ -E 1 S and Gctf 39 for ABCG2 EQ -ATP. Image processing. Particles were picked automatically using Gautomatch (http:// www.mrc-lmb.cam.ac.uk/kzhang/), resulting in an ABCG2 EQ -E 1 S dataset of 168,184 particles-processed with CryoSPARC 40 -and an ABCG2 EQ -ATP dataset of 1,128,170 particles, processed with RELION 41 . In both cases, 2D classification yielded at least 12 representative classes, containing 62,616 particles for ABCG2 EQ -E 1 S and 543,142 particles for ABCG2 EQ -ATP. These classes were used for ab initio reconstruction (applying either C1 or C2 symmetry).
For ABCG2 EQ -E 1 S, the resulting 3D models were used as a starting point for heterogeneous 3D refinement with three classes. Subsequent homogeneous refinements of all three classes (applying C2 symmetry) separately yielded maps that were very alike, with the maps for the two largest classes (corresponding to 38.7% and 32.6% of particles) having very similar densities in the substrate-binding cavity of ABCG2, and the map of smaller class (corresponding to 28.5% of the particles) having some additional density underneath the substrate density (which was only visible at noise level in the other classes). Therefore, we combined particles of the two largest classes (42,790 particles in total) from the 3D heterogeneous refinement and refined (applying C2 symmetry) against the heterogeneous refinement map of the largest class. This resulted in a map with a resolution of 3.58 Å, which was sharpened with an automatically calculated B-factor of −82.6 Å 2 . For validation, all refinements were also performed using C1 symmetry.
For ABCG2 EQ -ATP, initial 3D classification into three classes resulted in one outstanding class, containing 51.8% of particles (corresponding to 288,447 particles) with clear secondary-structure elements. This class was 3D-refined, applying C2 symmetry and a soft mask, resulting in a 3D reconstruction with an overall resolution of 3.14 Å. For nanodisc subtraction, the ABCG2 EQ -ATP map was segmented in Chimera (using Segger) and the resulting nanodisc-only map was used to calculate projections, which were subsequently subtracted from the experimental particles. A soft mask, in which the subtracted density from the experimental particles was white (1) and the rest of the protein and the solvent were black (0), was generated by low-passing the nanodisc map to 15 Å and expanding the mask by 4 pixels with a soft edge of 6 pixels. The nanodisc-free experimental particles were used in further 3D refinements, which resulted in an electron microscopy map at a resolution of 3.09 Å (B-factor of −136 Å 2 ), using the low-passed ABCG2 EQ -ATP map without nanodisc density as a reference. This map was used for ABCG2 EQ -ATP model building. Subsequent 3D classification in C1 symmetry, without applied alignments, was carried out in an effort to improve the EL3 density; however, despite extensive efforts the inherent flexibility of EL3 in this conformation prohibited its accurate modelling.
All resolutions were estimated with the Fourier shell correlation (FSC) 0.143 cut-off criterion 42 . ResMap 43 was used to calculate the local resolution maps. Model building and refinement. For the ABCG2 EQ -E 1 S structure, we used the post-processed map at an overall resolution of 3.58 Å. To generate an initial model, we docked the ABCG2-MZ29-Fab structure (Protein Data Bank 6ETI) into the electron microscopy density using Coot 44 , and carried out manual fitting and modifications where the resolution allowed. The E 1 S coordinates and restraints were generated using eLBOW 45 and fitted into the electron microscopy density using Coot. For the ABCG2 EQ -ATP structure, we used the postprocessed, nanodisc-subtracted map at an overall resolution of 3.09 Å. The electron microscopy density was of excellent quality and allowed for the accurate building of ABCG2, ATP and magnesium from the ligand library in Coot, using the ABCG2-MZ29-Fab structure (PDB: 6ETI) as a template. For both structures, the complete models were refined against the working maps in PHENIX 46 using the program phenix.real_space_refine. For the final round of model refinement, we performed global real-space refinement with standard geometry restraints as well as rotamer, Ramachandran plot, C-beta, non-crystallographic symmetry and secondary-structure restraints, coupled to reciprocal-space refinement of the B-factors. The quality of the final models was analysed by MolProbity 47 and the refinement statistics are given in Extended Data Table 1 . To validate the refinement, we introduced random shifts (mean value of 0.3 Å) into the coordinates of the final refined models using the program phenix.pdbtools 46 , followed by refinement with phenix.real_space_refine (using the same parameters as described before) against the first unfiltered half-map (half-map 1). The overlay between the FSC curve of the model with random displacements refined against half-map1 versus half-map 1 and the FSC curve of the same model versus half-map 2 (against which it was not refined) indicated that no over-refinement took place. 
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Extended Data Fig. 6 | Cryo-EM map generation, data processing and atomic-model refinement of ABCG2 EQ -ATP. a, Twelve representative 2D class averages of the final round of 2D classification, sorted in decreasing order by the number of particles assigned to each class. b, FSC from the RELION auto-refine procedure of the unmasked half-maps (blue), the half-maps after masking (green), and the half-maps after masking and correction for the influence of the mask (pink). A horizontal dotted line (blue) is drawn for the FSC = 0.143 criterion. For both the unmasked and the corrected FSC curves, their intersection with the FSC = 0.143 and the FSC = 0.5 lines are marked by arrows, and the resolutions at these points are indicated. c, FSC curve of the final 3.09 Å refined model versus the map against which it was refined (FSC full ; black line). FSC curves of the final refined model with introduced shifts (mean value of 0.3 Å) versus the first of two independent half-maps (half-map 1, against which it was refined; FSC work ; green line) or the same model versus the second independent half-map (against which it was not refined; FSC half2 ; red line) are also shown. d, Flow chart for cryo-EM data processing and structure determination of the ABCG2 EQ -ATP complex. The map used for model building is indicated by a red square. e, Full view of the RELION local-resolution-filtered map of ABCG2 EQ -ATP, coloured by local resolution in Å as calculated by ResMap, with the clipping plane in the middle of the molecule. f, Angular distribution plot for the final reconstruction. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Sample size
No statistical methods were used to predetermine sample size. For the ATPase assays (Figure 2e , Extended Data Figures 1e, 2b-f and 5) at least three technical replicates (same batch of liposomes or nanodiscs) were completed with four time points recorded for each replicate. For the transport assays ( Figure 2f ) at least four technical replicates were completed. For all bar graphs (Figures 2e,f and Extended Data Figure  2d ,e) the mean rate for each technical replicate has been plotted. Source Data has been provided.
Data exclusions No data excluded
Replication
All replicates were successful. The experimental conditions described in the Methods and/or referenced were adhered to as strictly as possible.
Randomization Animals and humans were not used in the study. Randomisation was not applicable as we used predetermined samples, conditions and time points in our assays.
Blinding
Animals and humans were not used in the study. Blinding was not applicable as we used predetermined samples, conditions and time points in our assays.
Reporting for specific materials, systems and methods The 5D3-antibody (reference 15 in the manuscript) was provided by B.Sorrentino whom we thank in the acknowledgments.
Validation
The 5D3-antibody was generated specifically for ABCG2 and has been biochemically validated (references 13 and 14 in the manuscript).
Eukaryotic cell lines Policy information about cell lines
Cell line source(s) HEK293 EBNA (Thermo Fisher Scientific).
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